Courtney Nickles, NP
Family · Terre Haute, INNPI 1972269488
Payments from drug & device makers
Across 344 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$1K
- Actelion Pharmaceuticals US, Inc.$497
- Harmony Biosciences LLC$423
- Regeneron Healthcare Solutions, Inc.$385
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,04095%
- Education$3985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $1,485 |
| GSK | 82 | $1,206 |
| Boehringer Ingelheim | 46 | $1,037 |
| Actelion Pharmaceuticals US, Inc. | 17 | $497 |
| Harmony Biosciences LLC | 19 | $423 |
| Regeneron Healthcare Solutions, Inc. | 13 | $385 |
| Jazz Pharmaceuticals Inc. | 9 | $305 |
| United Therapeutics Corporation | 12 | $264 |
| Sanofi | 10 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $202 |
| Mylan Specialty L.p. | 15 | $184 |
| Axsome Therapeutics, Inc. | 7 | $155 |
| Amgen | 8 | $147 |
| Merck | 7 | $145 |
| Mallinckrodt Hospital Products Inc. | 4 | $112 |
| Philips North America LLC | 5 | $81 |
| Insmed, Inc. | 4 | $78 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Grifols USA, LLC | 3 | $50 |
| Novartis | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Genentech USA, Inc. | 2 | $34 |
| Electromed, Inc. | 4 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $30 |
| Viatris Specialty LLC | 1 | $29 |
| Pulmonx Corporation | 2 | $27 |
| Baxter Healthcare | 1 | $24 |
| Verona Pharma, Inc. | 1 | $24 |
| Masimo Corporation | 1 | $22 |
| Novo Nordisk | 1 | $17 |
| Bayer | 1 | $17 |
| ZOLL Respicardia, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,437 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 61 | $828,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 549 | $453,878 |
| WakixPitolisant Hcl | 14 | $215,831 |
| Dupixent PenDupilumab | 33 | $126,820 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $110,385 |
| Dupixent SyringeDupilumab | 24 | $85,648 |
| Breo ElliptaFluticasone/Vilanterol | 119 | $64,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $63,348 |
| Spiriva RespimatTiotropium Bromide | 69 | $44,533 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $28,919 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $27,210 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 88 | $12,645 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 452 | $11,090 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $10,163 |
| SunosiSolriamfetol Hcl | 11 | $9,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,037 | $912,115199 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,206 | $549,914726 claims |
| Harmony Biosciences LLCWakix | $423 | $215,83114 claims |
| Grifols USA, LLCProlastin C | $50 | $110,38512 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,485 | $72,674108 claims |
| Axsome Therapeutics, Inc.Sunosi | $155 | $9,43211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.